ONCOCROSS

We identified a new indication of a drug candidate in Phase II.

We analyzed the transcriptome data of a new drug candidate that is in Phase II clinical trial, an asset of our collaborating pharmaceutical company. RAPTOR AI™ predicted that the drug candidate will show high efficacy in the liver disease treatment. We validated the efficacy through in vitro and in vivo validation and currently planning a clinical trials after filing a patent application. Our partner pharmaceutical company was able to add a clinical stage pipeline that has high unmet medical needs while saving 95% of the cost and almost 7 years that is required to reach phase I from early drug discovery.

The 1st L/O from an AI Biotech to a traditional pharmaceutical company.

We set sarcopenia as a target disease and ran RAPTOR AI™ to search for the drugs that will show efficacy in treating the disease. We identified two drugs that can show high efficacy when used simultaneously and validated them through in vitro and in vivo studies. We licensed out to Korea Pharma, which recorded the 1st L/O deal of an AI-developed drug from an AI Biotech to a traditional pharmaceutical company.

With ONCO-RAPTOR AI™, we identified the most optimal cancer types for the anti-cancer drug preparing to begin clinical trials.

A pharmaceutical company was preparing for clinical trials for the anti-cancer drug with 5 specific cancer types. They requested us to predict the optimal cancer types for their drug. Using ONCO-RAPTOR AI™ we identified the 5 optimal cancer types, which 4 types matched with their clinical design, but 1 type showed a poor prognosis if administered to that specific cancer patients. We presented our result and the company redesigned clinical trials according to our predicted types and began global clinical trials which is currently ongoing.

ONCOfind AI™, with the highest accuracy in Korea, will identify the primary cancer site.

CUP is a cancer type which metastasized cancer cells are found but the primary tumor site is unknown, and accounts for 3-5% of all cancers. Immunohistochemical staining is used as a conventional method of detect the primary tumor site, but the accuracy is only at around 65%. Currently there are no CUP screening service providers in Korea and only 5-6 service providers exist globally. However, their accuracy ranges between 70-90%. ONCOfind AI™ shows accuracy of upto 99.8% in identifying the primary site within 42 types of cancers.